Phase
Condition
Inflammatory Bowel Disease
Ulcers
Ulcerative Colitis
Treatment
SOR102
Placebo
Clinical Study ID
Ages 18-75 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
Male or females, of any ethnic origin.
Established diagnosis of UC by standard criteria for >3 months.
Disease evaluable by sigmoidoscopy.
Mildly to severely active UC as determined by central reader in combination withother assessments of disease
Exclusion
Key Exclusion Criteria:
Any diagnosis of IBD except for UC.
History of fistula(e), strictures or surgery, known intestinal obstruction, ordiagnosis of toxic megacolon.
Concurrent use of any biologic drug.
Prior primary efficacy failure or secondary loss of response to more than onebiologic or new small molecule therapy (i.e., JAK inhibitors or S1P receptormodulators) indicated for the treatment of UC. This does not include priordiscontinuation due to drug intolerance.
Study Design
Connect with a study center
Arensia Exploratory Medicine
Tbilisi,
GeorgiaSite Not Available
Arensia Exploratory Medicine
Kyiv,
UkraineSite Not Available
MAC Clinical Research
Manchester,
United KingdomSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.